Ascelia Pharma, based in Malmö, Sweden, announced that its product Orviglance received Orphan Drug Designation from the FDA.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ascelia Pharma, based in Malmö, Sweden, announced that its product Orviglance received Orphan Drug Designation from the FDA.